References
- Janssen Biotech Inc. Remicade® (infliximab) US prescribing information. Horsham, PA: Janssen Biotech Inc; 2017 October [cited 2018 May 8]. Available from: http://www.remicade.com/shared/product/remicade/prescribing-information.pdf
- European Medicines Agency. Remicade (infliximab) summary of product characteristics. European Medicines Agency. 2018 November 15 [cited 2018 Nov 27]. Available from: https://www.ema.europa.eu/documents/product-information/remicade-epar-product-information_en.pdf
- Weise M, Bielsky MC, De Smet K, et al. Biosimilars: what clinicians should know. Blood. 2012;120:5111–5117.
- World Health Organization. Guidelines on evaluation of similar biotherapeutic products (SBPs). October 2009 [cited 2018 May 8]. Available from: http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf
- US Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product. 2015 April [cited 2018 May 8]. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf
- European Medicines Agency, Committee for medicinal products for human use (CHMP). Guideline on similar biological medicinal products. CHMP/437/04 Rev. 2014 October 23 [cited 2018 May 8]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf
- Pfizer Inc. Ixifi™ (infliximab-qbtx) for injection. US prescribing information. New York, NY: Pfizer Inc; 2017 December [cited 2018 May 8]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761072s000lbl.pdf
- European Medicines Agency. Zessly (Infliximab). Summary of product characteristics. [cited 2018 Nov 27]. Available from: https://www.ema.europa.eu/documents/product-information/zessly-epar-product-information_en.pdf
- Derzi M, Johnson TR, Shoieb AM, et al. Nonclinical evaluation of PF-06438179: a potential biosimilar to Remicade® (infliximab). Adv Ther. 2016;33:1964–1982.
- Palaparthy R, Udata C, Hua SY, et al. A randomized study comparing the pharmacokinetics of the potential biosimilar PF-06438179/GP1111 with Remicade(R) (infliximab) in healthy subjects (REFLECTIONS B537-01). Expert Rev Clin Immunol. 2018;14:329–336.
- Cohen SB, Alten R, Kameda H, et al. A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy. Arthritis Res Ther. 2018;20:155.
- US Food and Drug Administration. Guidance for industry. Clinical pharmacology data to support a demonstration of biosimilarity to a reference product. Silver Spring, MD: US Department of Health and Human Services, US Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER); 2016 December [cited 2018 May 8]. Available from: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM397017.pdf
- European Medicines Agency. Committee for medicinal products for human use (CHMP). Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. London: European Medicines Agency; 2014 December 18 [cited 2018 May 8]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf
- Buurman DJ, Maurer JM, Keizer RJ, et al. Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice. Aliment Pharmacol Ther. 2015;42:529–539.
- Fasanmade AA, Adedokun OJ, Blank M, et al. Pharmacokinetic properties of infliximab in children and adults with Crohn’s disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther. 2011;33:946–964.
- Fasanmade AA, Adedokun OJ, Ford J, et al. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol. 2009;65:1211–1228.
- Fasanmade AA, Adedokun OJ, Olson A, et al. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int J Clin Pharmacol Ther. 2010;48:297–308.
- Ternant D, Ducourau E, Perdriger A, et al. Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis. Br J Clin Pharmacol. 2014;78:118–128.
- Ahn JE, Karlsson MO, Dunne A, et al. Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn. 2008;35:401–421.
- Wählby U, Thomson AH, Milligan PA, et al. Models for time-varying covariates in population pharmacokinetic-pharmacodynamic analysis. Br J Clin Pharmacol. 2004;58:367–377.
- Ette EI. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol. 1997;37:486–495.
- Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol. 2013;2:e38.
- Bergstrand M, Karlsson MO. Handling data below the limit of quantification in mixed effect models. AAPS J. 2009;11:371–380.
- Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet. 2007;46:645–660.
- Savic RM, Karlsson MO. Importance of shrinkage in empirical Bayes estimates for diagnostics: problems and solutions. AAPS J. 2009;11:558–569.
- Xu Z, Seitz K, Fasanmade A, et al. Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. J Clin Pharmacol. 2008;48:681–695.